Zoetis (NYSE:ZTS) Price Target Cut to $130.00 by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan cut Zoetis’s price target to $130 from $190, while keeping an overweight rating on the stock.
• Zoetis reported Q1 EPS of $1.53 versus the $1.60 estimate and revenue of $2.26 billion, both below expectations, and management lowered FY2026 EPS guidance to $6.85–$7.00.
• The stock fell to $81.64 on heavy trading, and analysts are mixed overall with a Hold consensus price target of $141.25.

Zoetis (NYSE:ZTS - Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $190.00 to $130.00 in a research note issued on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 59.25% from the company's previous close.

Several other analysts also recently issued reports on ZTS. William Blair reissued an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. Leerink Partners reissued a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. Piper Sandler reissued a "neutral" rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. UBS Group set a $99.00 target price on Zoetis in a research note on Friday. Finally, Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $141.25.

Zoetis Price Performance

ZTS traded down $5.68 on Friday, hitting $81.64. 11,380,174 shares of the company's stock traded hands, compared to its average volume of 4,528,826. The company's 50 day simple moving average is $118.49 and its 200-day simple moving average is $123.70. The firm has a market cap of $34.34 billion, a price-to-earnings ratio of 13.59, a P/E/G ratio of 1.71 and a beta of 0.87. Zoetis has a one year low of $81.10 and a one year high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts anticipate that Zoetis will post 7.01 EPS for the current year.

Hedge Funds Weigh In On Zoetis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Asset Management Inc boosted its holdings in Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company's stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Nordea Investment Management AB boosted its holdings in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the period. Seilern Investment Management Ltd boosted its holdings in Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company's stock valued at $41,957,000 after acquiring an additional 261,155 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Zoetis by 134.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company's stock valued at $205,290,000 after acquiring an additional 935,432 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its holdings in Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company's stock valued at $43,235,000 after acquiring an additional 18,040 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Some market participants view the sell‑off as an opportunity: commentary highlights durable secular trends in pet humanization, strength in livestock and international segments, and analyst notes that the pullback may be excessive for long‑term holders. QuiverQuant: Opinions on Q1 Earnings Miss and Guidance Cut
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript that clarify drivers of the quarter (pricing, demand, product mix) and the assumptions behind the updated guidance — worth reviewing for details on timing of any recovery. Seeking Alpha: Q1 2026 Earnings Call Transcript
• Negative Sentiment: Zoetis missed Q1 estimates (reported $1.53 EPS vs. ~ $1.60 consensus) and revenue of $2.26B fell short of expectations. Management trimmed FY‑2026 EPS guidance to $6.85–7.00 (consensus ~7.03) and set revenue guidance of $9.7–10.0B, signaling slower near‑term growth. Zacks: Q1 Earnings Lag Estimates, 2026 View Cut
• Negative Sentiment: U.S. companion‑animal demand showed marked weakness (reports cite an ~11% drop in U.S. companion animal revenue), with pricing pressure and increased generic competition hitting key products — the core domestic business outlook is the primary near‑term risk. Benzinga: US Pet Care Demand Is Weak - Zoetis Cuts Outlook
• Negative Sentiment: A shareholder law firm (Ademi LLP) announced an investigation into possible securities‑fraud claims tied to Zoetis’ disclosures — this raises legal/ reputational risk and could amplify volatility depending on findings. PR Newswire: Shareholder Alert - Ademi LLP Investigation

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.